Pacira BioSciences, Inc. (PCRX): Price and Financial Metrics

Pacira BioSciences, Inc. (PCRX): $33.15

0.49 (-1.46%)

POWR Rating

Component Grades








Add PCRX to Watchlist
Sign Up

PCRX Price/Volume Stats

Current price $33.15 52-week high $58.10
Prev. close $33.64 52-week low $32.67
Day low $32.97 Volume 260,059
Day high $34.29 Avg. volume 550,140
50-day MA $36.19 Dividend yield N/A
200-day MA $39.45 Market Cap 1.54B

PCRX Stock Price Chart Interactive Chart >


  • Growth is the dimension where PCRX ranks best; there it ranks ahead of 95.94% of US stocks.
  • The strongest trend for PCRX is in Quality, which has been heading up over the past 179 days.
  • PCRX's current lowest rank is in the Momentum metric (where it is better than 9.4% of US stocks).

PCRX Stock Summary

  • With a one year PEG ratio of 518, PACIRA BIOSCIENCES INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94.11% of US stocks.
  • With a year-over-year growth in debt of -25.34%, PACIRA BIOSCIENCES INC's debt growth rate surpasses merely 12.62% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PCRX comes in at 14.36% -- higher than that of 87.69% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PACIRA BIOSCIENCES INC are STER, CPRX, CVLT, ZIP, and QTRX.
  • Visit PCRX's SEC page to see the company's official filings. To visit the company's web site, go to

PCRX Valuation Summary

  • In comparison to the median Healthcare stock, PCRX's price/sales ratio is 21.05% higher, now standing at 2.3.
  • Over the past 154 months, PCRX's EV/EBIT ratio has gone up 74.7.

Below are key valuation metrics over time for PCRX.

Stock Date P/S P/B P/E EV/EBIT
PCRX 2023-09-18 2.3 1.9 -335.0 69.4
PCRX 2023-09-15 2.3 1.9 -341.8 70.5
PCRX 2023-09-14 2.4 2.0 -353.3 72.2
PCRX 2023-09-13 2.4 2.0 -348.0 71.4
PCRX 2023-09-12 2.3 1.9 -343.3 70.7
PCRX 2023-09-11 2.3 1.9 -339.3 70.1

PCRX Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at 99.84%.
  • The 2 year net income to common stockholders growth rate now stands at 44796.51%.
  • Its 5 year net cashflow from operations growth rate is now at 100.19%.
Over the past 33 months, PCRX's revenue has gone up $233,036,000.

The table below shows PCRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 654.062 126.452 20.881
2022-06-30 614.318 144.085 39.234
2022-03-31 580.497 144.413 38.439
2021-12-31 541.533 125.717 41.98
2021-09-30 513.313 149.169 61.625
2021-06-30 503.075 128.663 174.084

PCRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PCRX has a Quality Grade of C, ranking ahead of 72.8% of graded US stocks.
  • PCRX's asset turnover comes in at 0.394 -- ranking 116th of 681 Pharmaceutical Products stocks.
  • BCDA, NVAX, and RDHL are the stocks whose asset turnover ratios are most correlated with PCRX.

The table below shows PCRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.394 0.738 0.064
2021-03-31 0.381 0.731 0.042
2020-12-31 0.411 0.727 0.042
2020-09-30 0.451 0.729 0.029
2020-06-30 0.491 0.740 0.018
2020-03-31 0.536 0.749 0.030

PCRX Price Target

For more insight on analysts targets of PCRX, see our PCRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $79.00 Average Broker Recommendation 1.5 (Moderate Buy)

Pacira BioSciences, Inc. (PCRX) Company Bio

Pacira Pharmaceuticals develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company was founded in 2006 and is based in Parsippany, New Jersey.

PCRX Latest News Stream

Event/Time News Detail
Loading, please wait...

PCRX Latest Social Stream

Loading social stream, please wait...

View Full PCRX Social Stream

Latest PCRX News From Around the Web

Below are the latest news stories about PACIRA BIOSCIENCES INC that investors may wish to consider to help them evaluate PCRX as an investment opportunity.

Qualcomm downgraded, Wingstop upgraded: Wall Street's top analyst calls

Qualcomm downgraded, Wingstop upgraded: Wall Street's top analyst calls

Yahoo | August 3, 2023

Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated

Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.

Yahoo | August 2, 2023

Pacira BioSciences Reports Second Quarter 2023 Financial Results

-- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2023. Second Quarter 2023 Financial Highlights Total revenues of $169.5 millionNet product sales of $135.1 million for EXPAREL, $29.3 million for ZILRETTA, and $4.4 million for iovera°Net income of $25.8 mi

Yahoo | August 2, 2023

10 Best Small Cap Pharma Stocks to Buy

In this piece, we will take a look at the ten best small cap pharma stocks to buy. If you want to skip a primer on small cap investing and want to jump ahead to the top five stocks in this piece, then head on over to 5 Best Small Cap Pharma Stocks to Buy. […]

Yahoo | July 28, 2023

Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023

TAMPA, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 2, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allow

Yahoo | July 26, 2023

Read More 'PCRX' Stories Here

PCRX Price Returns

1-mo -11.32%
3-mo -17.25%
6-mo -15.30%
1-year -38.55%
3-year -45.21%
5-year -34.36%
YTD -14.14%
2022 -35.83%
2021 0.55%
2020 32.10%
2019 5.30%
2018 -5.76%

Continue Researching PCRX

Want to see what other sources are saying about Pacira BioSciences Inc's financials and stock price? Try the links below:

Pacira BioSciences Inc (PCRX) Stock Price | Nasdaq
Pacira BioSciences Inc (PCRX) Stock Quote, History and News - Yahoo Finance
Pacira BioSciences Inc (PCRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!